These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25640673)

  • 1. Cognition as a target in major depression: new developments.
    Solé B; Jiménez E; Martinez-Aran A; Vieta E
    Eur Neuropsychopharmacol; 2015 Feb; 25(2):231-47. PubMed ID: 25640673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive remission: a novel objective for the treatment of major depression?
    Bortolato B; Miskowiak KW; Köhler CA; Maes M; Fernandes BS; Berk M; Carvalho AF
    BMC Med; 2016 Jan; 14():9. PubMed ID: 26801406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.
    McIntyre RS; Xiao HX; Syeda K; Vinberg M; Carvalho AF; Mansur RB; Maruschak N; Cha DS
    CNS Drugs; 2015 Jul; 29(7):577-89. PubMed ID: 26290264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.
    Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D
    Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.
    Peyrovian B; Rosenblat JD; Pan Z; Iacobucci M; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():387-404. PubMed ID: 30738126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive dysfunction in unipolar depression: implications for treatment.
    Trivedi MH; Greer TL
    J Affect Disord; 2014 Jan; 152-154():19-27. PubMed ID: 24215896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder.
    Pan Z; Grovu RC; Cha DS; Carmona NE; Subramaniapillai M; Shekotikhina M; Rong C; Lee Y; McIntyre RS
    CNS Neurol Disord Drug Targets; 2017; 16(8):891-899. PubMed ID: 28933261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive impairment in major depressive disorder.
    Pan Z; Park C; Brietzke E; Zuckerman H; Rong C; Mansur RB; Fus D; Subramaniapillai M; Lee Y; McIntyre RS
    CNS Spectr; 2019 Feb; 24(1):22-29. PubMed ID: 30468135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice.
    Papakostas GI
    J Clin Psychiatry; 2014 Jan; 75(1):8-14. PubMed ID: 24345473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Potential Procognitive Effects of Modafinil in Major Depressive Disorder: A Systematic Review.
    Vaccarino SR; McInerney SJ; Kennedy SH; Bhat V
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31599501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.
    McDermott CL; Gray SL
    Ann Pharmacother; 2012 Apr; 46(4):599-605. PubMed ID: 22414791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.
    Keefe RS; McClintock SM; Roth RM; Doraiswamy PM; Tiger S; Madhoo M
    J Clin Psychiatry; 2014 Aug; 75(8):864-76. PubMed ID: 25099527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social cognition.
    Patin A; Hurlemann R
    Handb Exp Pharmacol; 2015; 228():271-303. PubMed ID: 25977087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI).
    McIntyre RS; Lee Y
    Curr Opin Psychiatry; 2016 Jan; 29(1):48-55. PubMed ID: 26575300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report.
    Freeman MP; Fava M; Lake J; Trivedi MH; Wisner KL; Mischoulon D
    J Clin Psychiatry; 2010 Jun; 71(6):669-81. PubMed ID: 20573326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vortioxetine: A new alternative for the treatment of major depressive disorder.
    Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.